Scholar Rock Holding Corp experienced a notable surge in stock price, driven by recent positive developments.
Scholar Rock Holding Corp (NASDAQ:SRRK) went up yesterday by 6.29%, closing at CA$51.19. This increase follows significant news regarding the company's recent employee inducement grants and the FDA approval of its treatment for spinal muscular atrophy.
Advertisement
Scholar Rock Holding Corp
SRRK.US
SRRK.US
Scholar Rock Holding Corp
WealthAwesomeMarket cap
$6.23B
52W high
$61.76
52W low
$27.07
1W change
+2.38%
Beta
0.68
Analyst Price Targets
Based on 10 analysts covering SRRK · as of Sep 23, 2026
Wall Street analysts forecast SRRK stock price to rise 37.5% over the next 12 months.
Consensus
Strong Buy4.60 / 5.00
Avg. Target
C$70.38
+37.5% Upside
Previously C$69.94 on Sep 17, 2026
Current Price
C$51.19
Last close
Analyst Breakdown (10 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SRRK's historical volatility
30-Day Vol
48.2%
Annualized
90-Day Vol
48.7%
Annualized
Trend (90d)
-28.3%
Annualized drift
90d Mean
C$46.27
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$49.49 | C$41.91 – C$58.45 |
| 60 trading days | C$47.85 | C$37.83 – C$60.54 |
| 90 trading days | C$46.27 | C$34.69 – C$61.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors may view the recent surge in Scholar Rock's stock as a positive indicator of the company's growth potential, particularly following the FDA approval of ISEMBYLD and the strategic hiring of new talent.
6.29% Increase in Stock Price
Scholar Rock's stock price rose significantly after the announcement of key developments, reflecting investor optimism about the company's future prospects.
Bull case
The FDA's approval of ISEMBYLD opens up a substantial market opportunity for Scholar Rock. This treatment targets muscle loss in patients already receiving SMN2-targeted therapy. Positive results from the Phase 3 SAPPHIRE trial show that the treatment could improve motor function, which may drive demand and support the company's revenue growth.
Bear case
Despite the positive developments, challenges remain. The added treatment burden and costs associated with ISEMBYLD could limit patient access and insurance coverage. Additionally, safety concerns, particularly regarding fractures, may affect how well patients stick with the treatment and its overall adoption.
FDA Approval and Market Potential
Advertisement
Scholar Rock's recent FDA approval for ISEMBYLD marks a significant milestone for the company. This treatment aims to enhance muscle function in patients with spinal muscular atrophy, a condition that currently has limited treatment options. The approval not only validates Scholar Rock's innovative approach but also positions the company to capture a share of the growing market for neuromuscular treatments.
Strategic Hiring to Fuel Growth
In addition to the FDA approval, Scholar Rock announced the granting of inducement equity awards to ten new employees. This strategic move is aimed at bolstering the company's workforce as it prepares for the commercial launch of ISEMBYLD. By attracting top talent, Scholar Rock is positioning itself for future growth and operational success.
Challenges Ahead
Despite the positive news, Scholar Rock faces challenges that could impact its growth trajectory. The complexities of insurance coverage for ISEMBYLD and potential safety concerns related to the treatment may influence patient uptake. Investors will be watching closely to see how the company navigates these hurdles in the coming months.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
